kidney damage
AM-Pharma lays off staff and changes CEO after failed phase 3 trial of ilofotase alfa
Anika Sharma
After experiencing a setback in its phase 3 study for sepsis-associated acute kidney injury (SA-AKI), Dutch biotech company AM-Pharma is ...
